Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence

Imagem de Miniatura
Arquivos
art_FREIRE_Development_and_internal_validation_of_an_adrenal_cortical_2013.PDF (145.18 KB)
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
Citação
CLINICAL ENDOCRINOLOGY, v.79, n.4, p.468-475, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective To develop and internally validate a prognostic score to predict the risk of metastases or recurrence in patients with adrenal cortical carcinomas (ACC). Design Clinical, laboratory and pathological data from 129 ACC patients, treated in a tertiary centre, were retrospectively reviewed. Results Using a multivariate binary logistic regression analysis, we developed a prognostic score with five covariates: a functional pattern other than isolated hyperandrogenism, a tumour size >75cm, a primary tumour classified as T3/T4, the presence of microscopic venous invasion and a mitotic index >5/50 high-power fields. The prognostic score was calibrated according to the Hosmer-Lemeshow goodness-of-fit test (P=09329) and exhibited excellent overall performance (Brier score=00738). Finally, the discriminatory ability of the model, determined by the area under the ROC curve (A(ROC)), was near perfect (A(ROC), 09611; 95% CI, 092676-099552). The prediction model was internally validated with 200 bootstrap resamples and achieved excellent performance for estimating the risk of metastasis and recurrence in eight additional patients with apparently localized disease at diagnosis. Conclusion We developed and internally validated a prognostic score based on the clinicopathological data that are readily available to any attending physician. Our model can be used to accurately estimate the risk of unfavourable outcomes in ACC patients. This score could be beneficial for both patient counselling and the identification of patients in whom adjuvant mitotane is justified.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/4259
Referências
  1. Abiven G, 2006, J CLIN ENDOCR METAB, V91, P2650, DOI 10.1210/jc.2005-2730
  2. Aubert S, 2002, AM J SURG PATHOL, V26, P1612, DOI 10.1097/00000478-200212000-00009
  3. Dehner LP, 2009, PEDIATR DEVEL PATHOL, V12, P284, DOI 10.2350/08-06-0489.1
  4. de Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678
  5. Evans HL, 1996, AM J CLIN PATHOL, V105, P76
  6. Fassnacht M, 2011, NAT REV ENDOCRINOL, V7, P323, DOI 10.1038/nrendo.2010.235
  7. Fassnacht M, 2009, CANCER, V115, P243, DOI 10.1002/cncr.24030
  8. Fassnacht M, 2006, J CLIN ENDOCR METAB, V91, P4501, DOI 10.1210/jc.2006-1007
  9. Fassnacht M, 2010, CLIN ENDOCRINOL, V73, P561, DOI 10.1111/j.1365-2265.2010.03867.x
  10. Giordano TJ, 2009, CLIN CANCER RES, V15, P668, DOI 10.1158/1078-0432.CCR-08-1067
  11. Grubbs EG, 2010, ANN SURG ONCOL, V17, P263, DOI 10.1245/s10434-009-0716-x
  12. Harrison LE, 1999, ARCH SURG-CHICAGO, V134, P181, DOI 10.1001/archsurg.134.2.181
  13. Iasonos A, 2008, J CLIN ONCOL, V26, P1364, DOI 10.1200/JCO.2007.12.9791
  14. Keegan CE, 2002, TRENDS ENDOCRIN MET, V13, P200, DOI 10.1016/S1043-2760(02)00602-1
  15. Khan TS, 2000, ANN ONCOL, V11, P1281, DOI 10.1023/A:1008377915129
  16. Klein JD, 2011, J PEDIATR SURG, V46, P1201, DOI 10.1016/j.jpedsurg.2011.03.052
  17. Leboulleux S, 2010, EUR J ENDOCRINOL, V162, P1147, DOI 10.1530/EJE-09-1096
  18. MENDONCA BB, 1995, J UROLOGY, V154, P2004, DOI 10.1016/S0022-5347(01)66673-4
  19. Michalkiewicz E, 2004, J CLIN ONCOL, V22, P838, DOI 10.1200/JCO.2004.08.085
  20. Miller BS, 2010, LANGENBECK ARCH SURG, V395, P955, DOI 10.1007/s00423-010-0698-y
  21. Miller BS, 2010, WORLD J SURG, V34, P1380, DOI 10.1007/s00268-010-0532-2
  22. Moons KGM, 2002, J CLIN EPIDEMIOL, V55, P1054, DOI 10.1016/S0895-4356(02)00453-5
  23. Pereira Rosana Marques, 2004, Arq Bras Endocrinol Metabol, V48, P651, DOI 10.1590/S0004-27302004000500010
  24. RIBEIRO RC, 1990, J CLIN ONCOL, V8, P67
  25. Sandrini R, 1997, J CLIN ENDOCR METAB, V82, P2027, DOI 10.1210/jc.82.7.2027
  26. Schteingart DE, 2005, ENDOCR-RELAT CANCER, V12, P667, DOI 10.1677/erc.1.01029
  27. Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9
  28. Stojadinovic A, 2002, J CLIN ONCOL, V20, P941, DOI 10.1200/JCO.20.4.941
  29. Tang C K, 1975, Urology, V5, P691, DOI 10.1016/0090-4295(75)90135-1
  30. Terzolo M, 2007, NEW ENGL J MED, V356, P2372, DOI 10.1056/NEJMoa063360
  31. TERZOLO M, 2008, EFFICACY ADJUVANT MI
  32. Wajchenberg BL, 2000, CANCER, V88, P711, DOI 10.1002/(SICI)1097-0142(20000215)88:4<711::AID-CNCR1>3.0.CO;2-W
  33. WEISS LM, 1989, AM J SURG PATHOL, V13, P202, DOI 10.1097/00000478-198903000-00004
  34. Wieneke JA, 2003, AM J SURG PATHOL, V27, P867, DOI 10.1097/00000478-200307000-00001

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/18
Carregar mais